Change of site of intra-articular injection of hypertonic dextrose resulted in different effects of treatment

Most minimally invasive treatments for dysfunction of the temporomandibular joint (TMJ) are empirical, and aimed at the painful trigger points with the purpose of preventing muscular spasm and restoring normal function. In this prospective study I investigated whether the choice of site of injection of hypertonic dextrose affected the benefits of treatment of internal derangement and pain. I studied 72 patients with pain and clicking as a result of dysfunction of the TMJ. Patients were divided into four groups with four separate sites for intra-articular injection. Dextrose was injected into the superior joint space, inferior joint space, retrodiscal tissue, and anterior capsule injection. Results showed that the retrodiscal site was the most effective for reducing clicking and subsequently improving derangement, while the inferior joint space was the best site for the relief of pain, and the extracapsular site should be used in cases of hypermobility. In conclusion, the injection site should be selected according to the symptoms being treated, and could be used as an adjunct to other sites to improve outcome.     

注射用两性霉素B治疗艾滋病/HIV感染合并深部真菌感染的不良反应及防护

目的:为临床合理应用注射用两性霉素B(AMB)治疗人类免疫缺陷病毒(HIV)感染或艾滋病(AIDS)合并深部真菌感染提供参考。方法:收集某院2010年1月至2012年2月期间住院治疗的3 202例HIV/AIDS患者的临床资料,分析其中使用AMB治疗深部真菌感染患者的不良反应(ADR)发生及防护。结果:HIV/AIDS合并深部真菌感染患者948例,感染率为29.61%;899例使用AMB,其中18例出现ADR,发生率为2.00%。AMB静脉滴注的ADR主要表现为发热、腹泻、瘙痒、肝功能异常及血液系统毒性。及时停药或减量,同时对症治疗,可有效地减少、减轻药物的ADR。结论:AMB虽ADR多见,但其疗效确切,是治疗HIV/AIDS合并深部真菌感染比较安全、有效、经济的选择。只要合理用药,严密监测用药后患者病情进展,尽早发现ADR,及时采取有效措施,并将心理护理贯穿治疗始终,就能保证患者治疗的顺利进行。     

Establishment of safety evidence for Xingxue Shuxuening injection

OBJECTIVE： To systematically investigate the safety of Xingxue Shuxuening injection（SXN） in preand post-marketing, and to ensure clinical drug safety.METHODS： Strict quality control in raw herb selection and production processes was adopted and pharmacology research on SXN was performed by the drug manufacturing company, Heilongjiang ZBD Pharmaceutical Co., Ltd. We systematically reviewed the safety literature of Xingxue SXN. Adverse drug reaction（ADR） data of the drug, extracted from Spontaneous Reporting System（SRS）, and clinical characters based on 20 hospital information systems（HIS） in China, were analyzed. Large-scale prospective safety monitoring and Risk Minimization Action Plans（Risk MAPs） of XingxueSXN were carried out.RESULTS： The quality of SXN was stable and controllable when it was produced. Drug toxicology studies found no effect on rabbits with hemolytic or condensed, local stimulation and muscle stimulation, and no allergic reactions in guinea pigs. The ADRs of Xingxue SXN were dizziness, phlebitis,and vomiting based on SRS data. The injection did not conform to instructions in clinical practice when we analyzed HIS database, and patient＇s abnormal blood urea nitrogen levels may be related to the drug, when analyzed using the propensity score method. A nested case-control study was designed and performed to analyze the influencing factors of suspected allergic reactions to SXN. The study showed that patients with an allergy history were more prone to allergic reactions（P〈0.001）,and some medicine combinations could cause allergic reactions.CONCLUSION： These studies have established a body of evidence on Xingxue SXN safety, and provide a good model for Chinese medicine injection for clinical safety. The Xingxue SXN production process and toxicology research indicate the safety of the injection. However, the use of the injection is not consistent with instructed clinical practice.Xingxue SXN causes ADRs perhaps from inappropriate usage or its     

符合GMP要求的BM系列内循环二板式注塑机的结构性能及特点

本文简述了符合GMP要求的BM系列内循环二板直压式注塑机在锁模结构上的重大突破及其结构性能、特点--精密降耗、节省洁净、安全高效、高速便捷.     

川芎嗪注射液治疗新生儿缺氧缺血性脑病的临床疗效

目的分析川芎嗪注射液治疗新生儿缺氧缺血性脑病（HIE）患儿的近期临床疗效。方法选择我院的78例HIE患儿，随机分为川芎嗪注射液治疗组40例与对照组38例。对照组采用包括对症，支持，降颅内压，改善内环境等常规治疗；治疗组在常规治疗的基础上，加用川芎嗪注射液治疗，疗程10～14d。分别于治疗过程中观察患儿临床症状恢复情况。结果治疗组临床症状，前囟张力、意识障碍、肌张力、原始反射恢复时间及惊厥控制时间均短于对照组，且总有效率相差显著沪〈0．005）。结论HIE在常规治疗的基础上，早期应用川芎嗪注射液治疗，能缩短HIE的临床恢复时间，疗效显著，值得临床推广应用。     

肾上腺素大腿前外侧肌内注射抢救 严重过敏反应的临床效果观察

〔摘 要〕 目的：探讨肾上腺素大腿前外侧肌内注射抢救严重过敏反应的临床效果。方法：选择 2018 年 1 月至 2022 年 7 月东莞市长安医院收治的 60 例 Ⅱ ~ Ⅳ 级的严重过敏反应者，按照不同的使用肾上腺素给药方法，分为两组， 各 30 例。观察组针对 Ⅱ ~ Ⅳ 过敏反应患者，使用肾上腺素原液大腿中 1/3 前外侧深部肌内注射，针对 Ⅳ 级严重过 敏反应者，联合肾上腺素（1:10000）静脉注射。对照组针对 Ⅱ ~ Ⅳ 级过敏反应者，使用肾上腺素原液皮下注射，针 对 Ⅳ 级严重过敏反应者均予序贯肾上腺素（1:10000）静脉注射，比较干预前后两组患者生命体征变化情况，循环稳 定时间及肾上腺素总用量，以及干预期间不良反应情况。结果：干预后，两组患者心率、呼吸频率均低于干预前，平 均动脉压均高于干预前，且观察组患者心率、呼吸频率均低于对照组，平均动脉压高于对照组，差异具有统计学意义 （P ＜ 0.05）；观察组患者循环稳定时间短于对照组，肾上腺素总用量少于对照组，差异具有统计学意义（P ＜ 0.05）； 观察组患者不良反应发生率低于对照组，差异具有统计学意义（P ＜ 0.05）。结论：对于不同级别严重过敏反应者， 使用大腿中 1/3 前外侧深部肌内注射联合静脉注射肾上腺素（1:10000）的治疗效果均较好，且不良反应少。     

蟾酥注射液治疗原发性肺癌疼痛的疗效分析

目的研究蟾酥注射液治疗原发性肺癌疼痛的疗效及不良反应。方法选取2007年1月至2013年7月就诊的85例肺癌疼痛患者,采用随机区组设计方案,分为治疗组(43例)和对照组(42例)。治疗组患者采用静脉滴注蟾酥注射液10²0ml,1次/d。对照组患者口服曲马多缓释片10020ml,1次/d。对照组患者口服曲马多缓释片100²00mg,每12小时1次。观察两组患者的疗效和不良反应。结果治疗组患者完全缓解16例(37.2%),部分缓解13例(30.2%),轻度缓解4例(9.3%),总有效率为76.7%。对照组患者完全缓解15例(35.7%),部分缓解16例(38.1%),轻度缓解4例(9.5%),总有效率为83.3%。两组差异无统计学意义(P>0.05)。治疗组有2例患者出现不良反应,对症治疗后即可缓解,不影响继续用药及疗效。对照组有5例出现不良反应,其中3例自行缓解,2例对症治疗后即可缓解,不影响继续用药及疗效。结论蟾酥注射液有镇痛作用,不良反应轻,兼有抗肿瘤、提高免疫力等作用,是理想的治疗肺癌疼痛的药物。     

精密注塑机的最新技术进展及发展趋势

本文通过分析注塑机锁模结构、驱动方式的变化,从精密、高效、节能、环保等方面,阐述了精密注塑机的最新技术进展及发展趋势.